Introduction
============

In Germany, about one million people suffer from dementia,[@b1-ndt-8-141],[@b2-ndt-8-141] with 50% to 70% of these due to Alzheimer's disease (AD). Based on demographic changes, AD prevalence is predicted to increase by 50% in the next 25 years. The primary objective of current pharmacological AD therapy is to slow down disease progression and to preserve the capability for activities of daily life.[@b3-ndt-8-141]

Cholinesterase (CHE) inhibitors are a mainstay in the treatment of mild to moderate AD. Only oral treatments were available until rivastigmine (Exelon^®^; Novartis, Basel, Switzerland) was approved as the first transdermal antidementia drug in 2007. Transdermal patches provide continuous drug delivery and maintain rivastigmine concentrations within the optimal therapeutic window avoiding the peaks and troughs associated with oral administration. The rivastigmine patch was demonstrated to be as efficacious as the highest oral doses and with approximately three times fewer reports of gastrointestinal adverse events (AEs), such as nausea and vomiting.[@b4-ndt-8-141] Moreover, the once-daily application of the patch is supposed to improve compliance with the recommended dosing regimen. Better compliance may increase effectiveness and reduce caregiver burden, institutionalization rate, and costs. Given these advantages, the rivastigmine patch may be superior to oral CHE inhibitors and may advance the treatment of AD long-term.[@b5-ndt-8-141]

However, patients in clinical trials are known not to be representative of the total target population. Selection bias is particularly caused by excluding patients who do not respond to existing first-line treatments. Therefore, the current study aimed to verify the external validity of clinical trial data on the efficacy and tolerability of transdermal rivastigmine under daily routine conditions in Germany. A subgroup analysis was undertaken to elucidate the role of previous and concomitant medication.

Methods
=======

Study design
------------

This was a prospective, multicenter, observational study on the effectiveness and tolerability of rivastigmine patch for the treatment of AD in everyday practice in Germany. For each eligible patient, physicians were requested to collect data immediately prior to and about 1 month and 4 months after treatment initiation. The study was conducted from January to October 2008 in compliance with the Declaration of Helsinki and all applicable legal requirements.

Patients
--------

Outpatients with mild-to-moderate AD in conformity with the specification of the drug label were eligible if they had not previously been treated with rivastigmine. Patients had to be fully capable to contract and to make a decision about participation in the study. All included patients consented to the use of their pseudo-anonymized data.

Treatment
---------

As this was an observational study there were no protocol instructions on treatment. The provided product information specified to use the 5 cm^2^ patch corresponding to an initial dose of 4.6 mg rivastigmine per 24 hours for a minimum of 4 weeks first and to change to the 10 cm^2^ patch corresponding to the recommended effective dose of 9.5 mg rivastigmine per 24 hours as tolerability allows.

Outcome measures
----------------

Effectiveness was evaluated based on (a) the Mini-Mental State Examination (MMSE), a brief 30-point screening instrument for cognitive impairment; (b) the clock-drawing test (CDT) to assess on a 7-point scale visual--spatial construction, visual perception, and abstract conceptualization; (c) the Clinical Global Impression (CGI) of the patient as assessed on a 5-point scale by the attending physician; and (d) the caregivers' quality of life on the Caregiver Burden Scale (CBS), parts A and B. Part A included six statements on the caregiver (maximum 30 points) and part B included seven statements on the caregiver--patient relationship (maximum 35 points). Each statement was to be assessed on a 5-point scale with high scores representing high burden.

In addition, drug safety and tolerability were evaluated based on the monitoring of AEs and the physicians' global tolerability assessment per patient. For an evaluation of treatment practice and compliance, daily doses, dose adjustments, concomitant and previous medications, and premature discontinuation of the rivastigmine patch were recorded.

Data analysis
-------------

Diseases were classified according to the International Classification of Diseases, version 10; medications according to the *WHO Drug Dictionary* as of March 1st 2007; and AEs according to the *Medical Dictionary for Regulatory Activities*, version 11.1. All patients who gave informed consent and started treatment with rivastigmine patch based on the recommendation of their physician entered the analysis. Descriptive data analyses were performed using summary statistics for categorical and quantitative data. Continuous data were described as median, means, standard deviation (SD), minimum, maximum, and 25th and 75th percentiles. Stratification and categorization were based on clinical criteria. In case of qualitative variables the absolute and relative frequencies were calculated. In stratified analyses percentages were given per category and stratum. Safety analyses included tabulation of type and frequency of AEs on a patient and event basis. The role of premedication for effectiveness and tolerability was examined by a subgroup analysis comparing outcomes in patients who had previously been treated with other antidementia drugs (pretreated) and patients who received rivastigmine as the first antidementia drug (first-time treated). For inferential statistics a two-sided *t*-test at a significance level of 0.05 was used. All analyses were conducted with SAS for Windows (version 9.1; SAS Institute, Cary, NC).

Results
=======

Patient population
------------------

In 257 centers, 1113 patients, 614 women (55.2%) and 499 men (44.8%), with a mean age of 76.5 ± 7.5 (SD) years were enrolled; in 12.9% of patients onset of AD was categorized as early and in 61.5% as late; for 18.3% onset was not specified and 8.8% of patients had additional diagnoses associated with dementia. Patients were diagnosed with AD on average 1.0 ± 1.7 years (mean ± SD) prior to the baseline visit and first dementia symptoms manifested 1.2 ± 1.9 years before. About 42% of patients were included in the pretreated group. The most common previous treatments were other CHE inhibitors (24.5%). About two thirds (64.2%) switched to the rivastigmine patch due to lack of efficacy and about one third (32.4%) due to lack of tolerability. At baseline, first-time treated, and pretreated subgroups were comparable in demographic characteristics, but the disease in pretreated patients was further advanced ([Table 1](#t1-ndt-8-141){ref-type="table"}).

Treatment practice and compliance
---------------------------------

The study was completed by 92.8% of patients. The majority of these patients also attended both follow-up visits; 6.1% of patients attended one follow-up visit only and 1.1% of patients were lost to follow up without any post-treatment assessment. Patch treatment was discontinued within the 4 month observation period by 164 (14.7%) patients, on average 91 ± 43 days after initiation, due to AEs (6.0%), lack of compliance (3.1%) and/or efficacy (1.8%), for unknown (3.3%) or other reasons (3.0%). In compliance with the product information, 95.6% of patients started treatment at the recommended initial dose of 4.6 mg/24 hours ([Figure 1](#f1-ndt-8-141){ref-type="fig"}). In 62.3% of patients the dose was subsequently escalated to 9.5 mg/24 hours. In about one quarter of patients, the dose was not changed at all and 21.8% of patients remained on the low initial dose for the 4 month study period. For a minority of patients (2.7%) the dose was adjusted twice or decreased once.

At the initial visit, 29.0% of patients received comedication, most commonly antipsychotics (17.1%) and antidepressants (12.3%). The most frequently recorded antipsychotic drugs accounting for 86.3% of this drug class were risperidone, melperone, quetiapine, and pipamperone. Citalopram, mirtazapine, sertraline, and venlafaxine together accounted for 71.5% of all antidepressants given concomitantly. Within 4 months on transdermal rivastigmine, the proportion of patients taking psychotropic comedication overall decreased from 29.0% to 25.8% with 15.4% taking antipsychotics and 11% antidepressants; among these drug classes, greatest decreases showed pipamperone from 11.1% to 9.4% of patients and sertraline from 10.2% to 6.6% of patients, respectively.

Effectiveness
-------------

Patients showed no deterioration in disease-specific outcome measures. Between baseline and the end of the observation period (4 months), mean scores on the MMSE and the CDT significantly increased by 0.9 ± 3.4 (from 18.1 ± 5.7 to 18.8 ± 5.9; *P* \< 0.0001) and 0.3 ± 1.5 (from 3.2 ± 2.0 to 3.5 ± 2.2; *P* \< 0.0001), respectively. After 1 month, the attending physician rated the CGI in 50.9% of patients as better, in 45.6% as unchanged, and in 0.4% as worse (3.1% missing). After 4 months, the corresponding rates were 61.1%, 28.9%, and 3.1%, respectively (6.8% missing) ([Figure 2](#f2-ndt-8-141){ref-type="fig"}). The mean CBS-A and -B scores significantly decreased by 0.9 ± 3.4 (from initially 18.4 ± 6.1 to 17.3 ± 5.9 after 4 months; *P* \< 0.0001) and 1.2 ± 3.4 (from initially 15.8 ± 6.5 to 15.2 ± 6.1; *P* \< 0.0001), respectively.

Tolerability and safety
-----------------------

After 1 month of treatment, physicians rated tolerability as very good or good in 93.7% of patients and poor in 2.8% of patients (3.5% unknown or missing). After 4 months, it was still good or very good in 86.6% of patients and poor in 5.9% of patients (7.6% unknown or missing) ([Figure 3](#f3-ndt-8-141){ref-type="fig"}).

A total of 226 AEs were reported in 130 (11.7%) patients; of these, physicians deemed 166 at least possibly related to rivastigmine, 26 of them being serious. Potentially related AEs occurred in 104 patients (9.4%): 58 patients (5.2%) had one; 32 patients (2.9%) two; ten patients (0.9%) three; three patients (0.3%) four; and one patient (0.1%) five such AEs.

The most frequent AEs were erythema and nausea, and the most frequently affected system organ classes were skin and subcutaneous tissue disorders, gastrointestinal, psychiatric, and nervous system disorders ([Table 2](#t2-ndt-8-141){ref-type="table"}). More than half of the skin and subcutaneous tissue disorders occurred within the first 6 weeks of treatment. Psychiatric and nervous system disorders were less frequent than dermatological and gastrointestinal disorders, but these AEs were more often serious. Overall incidence rates of potentially rivastigmine-related AEs and serious AEs (SAEs) were 8.3% and 1.1% of patients, respectively. Severity was mild in 29.0%, moderate in 39.6%, and severe in 20.1% of AEs (11.2% missing). By the end of the study, patients had recovered from 72% and 61.6% of such AEs and SAEs, respectively, whereas 18.9% of AEs and 11.5% of SAEs in a total of 19 patients had not resolved yet. One fatal SAE was deemed probably drug-related by the investigator, a completed suicide after hallucination of a 93-year-old female patient, 49 days after treatment initiation.

Role of premedication
---------------------

Pretreated as compared to first-time treated patients tended to escalate earlier to the target dose (after 1 month 61.2% versus 54.5% on 9.5 mg/day), to remain longer in the trial (drop-out rates after 4 months, 5.6% versus 9.0%), and a higher proportion was on the target dose after 4 months (71.0% versus 64.9%), although none of these differences was actually significant. The decrease in the proportion of patients taking psychotropic comedication was more pronounced and significant in patients who had not been pretreated (from 27.1% to 22.6%; *P* \< 0.001). MMSE and the CGI improved under rivastigmine, regardless of whether patients were pre- or first-time treated. Over 4 months, the MMSE changed by 0.8 ± 3.4 in pretreated and by 0.9 ± 3.4 in first-time treated patients; the CGI improved in 61.3% and 60.9%, respectively (all *P* \> 0.1).

Discussion
==========

Rivastigmine was the first CHE inhibitor of which a patch formulation was approved for the treatment of mild to moderate AD.[@b4-ndt-8-141],[@b6-ndt-8-141] According to results from a double-blind, randomized, active- and placebo-controlled clinical trial, the Investigation of transDermal Exelon in ALzheimer's disease (IDEAL), transdermal rivastigmine provides superior tolerability at noninferior efficacy as compared to the capsule formulation. Through improved patients' compliance and adherence this may increase drug effectiveness. However, clinical trial data need to be verified in daily practice as external validity might be limited, in particular due to selection bias caused by inclusion and exclusion criteria.

In the IDEAL trial inclusion criteria were 50 to 85 years of age, an MRI-confirmed AD diagnosis not older than 1 year prior to inclusion, MMSE baseline scores between 10 and 20, and patients had to live with someone in the community or to be in daily contact with a caregiver. Exclusion criteria were advanced, severe, progressive, or unstable disease, an unconfirmed AD diagnosis, or another AD treatment within 4 weeks prior to randomization.[@b4-ndt-8-141],[@b6-ndt-8-141] Not all of these data were collected in the current study, but solely based on the age and MMSE criteria about 64% of the patient population -- although similar in size and likely representative of the total target population in Germany -- would have been excluded. This is much higher than one might expect from the overall screening failure rate of 18.4% in IDEAL if both populations were the same. Consequently, the patch-treated patients in this study were slightly older (76.5 ± 7.5 years versus 73.6 ± 7.9 years), significantly more often male (44.8% versus 32.0%), and had lower MMSE baseline scores (18.1 ± 5.7 versus 16.5 ± 3.0).

However, despite those differences in patient populations, effectiveness shown in this trial was well in line with corresponding results of IDEAL: MMSE scores significantly increased on average by 0.7 (0.9 in the first-time treated group) over 4 months versus 0.9 in the corresponding treatment arm of IDEAL.[@b4-ndt-8-141],[@b6-ndt-8-141] CDT scores increased in both studies by 0.3. Percentages of patients with improved CGI treated with transdermal rivastigmine were higher in the current study but this comparison is biased as the assessment method was different. CBS was not used in IDEAL, however decreasing scores in both Parts A and B in this study are in line with the distinct caregiver preference for the patch relative to capsules observed in IDEAL.[@b7-ndt-8-141]

In the current study, safety and tolerability of transdermal rivastigmine appeared even more favorable; however this has to be taken with caution. The lower discontinuation rate of 14.7% versus 21.8% in IDEAL might be due to the 2 months shorter treatment duration and the less rigid dose escalation to 9.5 mg/day after the first month. Actually, under routine conditions about one fifth of patients still remained on the initial dose of 4.6 mg/day over 4 months. By contrast, the difference in the percentage of patients discontinuing due to an AE (6.0% versus 9.6%) is quite small. However, one has to bear in mind that the AE monitoring in a GCP-compliant clinical trial is much closer and not comparable to that of the current observational study. This is clearly reflected by recording only 12% of patients having any AE whereas in the corresponding treatment arm of IDEAL 51% of patients had any AE. In IDEAL, the most common AEs were nausea (7.2%) and vomiting (6.2%), whereas the incidence of severe skin irritation was stated to be less than 10%. Apart from these administration site reactions, which were an endpoint rather than an AE in IDEAL, nausea and vomiting were also the most frequently observed single AEs in common practice.

Our results are also in line with those of several open-label studies demonstrating benefits from switching AD therapy to rivastigmine after other CHE inhibitors and particularly donepezil have failed in terms of efficacy or tolerability.[@b8-ndt-8-141],[@b9-ndt-8-141] An additional and rather specific benefit associated with the use of rivastigmine might be the reduction of psychotropic comedication. This may be a result of increased cholinergic function in the human limbic system and thalamus due to the inhibition of both acetylcholinesterase and butyrylcholinesterase by rivastigmine. The dual inhibition may contribute to a drug-saving effect as butyrylcholinesterase activity increases with AD progression and severity. Such a drug saving effect was first described in another observational study (EXALAN) using oral rivastigmine in a similar population and over a similar period of time.[@b10-ndt-8-141] In the current study, such a drug-sparing effect was also detectable with the transdermal formulation, although it was less striking. However, the effect sizes observed in both studies are not directly comparable as in the current study neither patients had to take any psychoactive medication for inclusion (as in EXALAN) nor were dose reductions recorded. In EXALAN, patients reducing psychotropic medication were shown to also gain the largest cognitive benefit from rivastigmine. Based on the small sample size, this could not be examined in the current study, but the proportion of patients who discontinued psychotropic comedication as well as the clinical benefit tended both to be higher in first-time treated as compared to pretreated patients. Whether such a drug sparing effect is indeed related to premedication or to different disease characteristics in both subgroups remains to be elucidated.

Conclusion
==========

In conclusion, our study confirmed the tolerability and effectiveness of transdermal rivastigmine in daily practice. Interestingly, the number of adverse events and the magnitude of cognitive improvement were similar in first- and pretreated patients and among subgroups of the latter. This further supports consideration of transdermal rivastigmine when other treatments have failed due to lack of either efficacy or tolerability. Whether rivastigmine has a direct drug-sparing effect on psychotropic comedication as seen in this and another observational study deserves further investigation in controlled clinical trials.
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###### 

Demographics and disease characteristics in first-time and pretreated patients

  ----------------------------------------------------------------------------
                                First-time treated\   Pretreated\   *P*
                                n = 638               n = 457       
  ----------------------------- --------------------- ------------- ----------
  Age (years)                   76.7 (7.7)            76.2 (7.2)    0.2536

  Sex                                                               0.6250

  • Male                        44.1%                 45.7%         

  • Female                      55.9%                 54.3%         

  AD due to ICD 10                                                  0.1345

  • Early onset AD              12.7%                 13.3%         

  • Late onset AD               59.3%                 64.8%         

  • AD NOS                      20.0%                 16.1%         

  • Other                       8.0%                  5.8%          

  Disease history (years)                                           

  • AD                          0.6 (1.5)             1.5 (1.9)     \<0.0001

  • Dementia                    0.7 (1.6)             1.7 (2.1)     \<0.0001

  Housing conditions                                                \<0.0001

  • Solitarily                  16.3%                 9.4%          

  • With family                 67.6%                 79.4%         

  • Homebound/assisted living   16.1%                 11.2%         
  ----------------------------------------------------------------------------

**Abbreviations:** AD, Alzheimer's disease; ICD 10, International Classification of Diseases, version 10; NOS, not otherwise specified.

###### 

Incidence of AEs and SAEs (by system organ class and preferred term) that physicians deemed at least possibly related to rivastigmine, (preferred terms listed only if total incidence ≥ 0.5%)

                                                         AE     SAE    Total                
  ------------------------------------------------------ ------ ------ ------- ----- ------ ------
  MedDRA system organ class                                                                 
  • preferred term                                                                          
  Total                                                  1113   100    1113    100   1113   100
  Skin and subcutaneous tissue disorders                 65     5.8    --      --    65     5.8
  • Dermatitis contact                                   10     0.9    --      --    10     0.9
  • Erythema                                             28     2.5    --      --    28     2.5
  • Pruritus                                             10     0.9    --      --    10     0.9
  Gastrointestinal disorders                             34     3.1    1       0.1   35     3.1
  • Nausea                                               19     1.7    --      --    19     1.7
  • Vomiting                                             10     0.9    --      --    10     0.9
  Psychiatric disorders                                  19     1.7    13      1.2   32     2.9
  • Restlessness                                         7      0.6    1       0.1   8      0.7
  Nervous system disorders                               10     0.9    4       0.4   14     1.3
  • Dizziness                                            8      0.7    1       0.1   9      0.8
  General disorders and administration site conditions   7      0.6    2       0.2   9      0.8
  Cardiac disorders                                      1      0.1    2       0.2   3      0.3
  Metabolism and nutrition disorders                     --     --     2       0.2   2      0.2
  Injury, poisoning, and procedural complications        --     --     1       0.1   1      0.1
  Renal and urinary disorders                            --     --     1       0.1   1      0.1
  Ear and labyrinth disorders                            1      0.1    0       0     1      0.1
  Immune system disorders                                1      0.1    --      --    1      0.1
  Investigations                                         1      0.1    --      --    1      0.1
  Respiratory, thoracic, and mediastinal disorders       1      0.1    --      --    1      0.1
  Total                                                  140    12.6   26      2.3   166    14.9

**Abbreviations:** AE, adverse event; SAE, serious adverse event; MedDRA, *Medical Dictionary for Regulatory Activities*.
